Results 111 to 120 of about 1,063 (182)

Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study. [PDF]

Int J Urol
Suzuki K, Khan N, Taguchi T, Hattori K, Chen G, Ghadessi M, Constantinovici N, Quintero V, Suzuki H.   +8 more
europepmc   +1 more source

Case report: Apalutamide-induced severe lethal cutaneous adverse effects in China. [PDF]

Front Immunol, 2023
Wang Q, Cao H, Zhang X, Wu H, Tang Z.
europepmc   +1 more source

The Therapeutic Potential of Spirooxindoles in Cancer: A Focus on p53-MDM2 Modulation. [PDF]

Pharmaceuticals (Basel)
Girgis AS, Zhao Y, Nkosi A, Ismail NSM, Bekheit MS, Aboshouk DR, Aziz MN, Youssef MA, Panda SS.   +8 more
europepmc   +1 more source

Comparative real-world study of apalutamide and darolutamide in Japanese patients with non-metastatic castration-resistant prostate cancer. [PDF]

BMC Urol
Ikeda M, Uemura K, Ito Y, Ito H, Kawahara T, Hasumi H, Teranishi JI, Makiyama K, Uemura H.   +8 more
europepmc   +1 more source

The impact of concomitant therapies on the efficacy and safety of relugolix in advanced prostate cancer. [PDF]

Future Oncol
Shore ND, George DJ, Spratt DE, De La Cerda J.   +3 more
europepmc   +1 more source

Comparative effectiveness of androgen receptor pathway inhibitor treatment intensification for metastatic hormone-sensitive prostate cancer in real-world patients. [PDF]

Investig Clin Urol
Lee CH, Kim S, Ku JY, Kim KH, Kang BJ, Goh HJ, Seo WI, Ha HK.   +7 more
europepmc   +1 more source

Synthesis of Thiohydantoin. III [PDF]

, 1914
Komatsu, Shigeru
core  

Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies. [PDF]

Future Oncol
Karsh LI, Bevans KB, Saad F, Chung BH, Oudard S, Brookman-May SD, McCarthy SA, Smith MR, Chi KN, Small EJ, Agarwal N.   +10 more
europepmc   +1 more source

Cost-effectiveness analysis of second-generation androgen receptor antagonists for the treatment of metastatic hormone-sensitive prostate cancer. [PDF]

Front Public Health
Yang Y, Chen YQ, Huang LZ, Chen Y.
europepmc   +1 more source

Apalutamide-induced severe hypothyroidism: case series and practice recommendations for thyroid management. [PDF]

Eur Thyroid J
David K, Van Crombrugge P, Van der Biest AM, D'Hondt F, Claessens F, Giesen A, Joniau S, Decallonne B.   +7 more
europepmc   +1 more source